WO1991004275A1 - Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques - Google Patents
Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques Download PDFInfo
- Publication number
- WO1991004275A1 WO1991004275A1 PCT/EP1990/001578 EP9001578W WO9104275A1 WO 1991004275 A1 WO1991004275 A1 WO 1991004275A1 EP 9001578 W EP9001578 W EP 9001578W WO 9104275 A1 WO9104275 A1 WO 9104275A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- ticks
- protecting
- grazing cattle
- new proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- the present invention relates to new proteins and their production.
- Hirudin is a polypeptide with a molecular weight of approximately 106,500.
- the invention relates to a new protein which has a molecular weight of about 15,000 daltons and the amino acid sequence at the amino terminus
- Muteins are to be understood as proteins that arise from the new protein through exchange, deletion and / or addition of amino acids or peptides in the protein chain without the effect of the new protein thereby changing significantly.
- the new protein can be isolated from ticks.
- the ticks are taken up in a buffer at pH 6 to 9, preferably 7.5.
- the insoluble constituents are centrifuged off.
- Inactive protein is precipitated from the solution thus obtained by adding trichloroacetic acid to a final concentration of 2.5% and removed by centrifugation.
- ether-soluble constituents are removed by extraction and the protein is then precipitated with cold acetone.
- the new protein can be isolated from the precipitated product by ion exchange and pH gradient chromatography.
- the protein described here is present in the ticks in a concentration between 1 - 100 ⁇ g / kg.
- the genetic information thus obtained for the protein can then be expressed in various host cells, such as eukaryotic cells, yeasts, Bacillus subtilis or E. coli, using known methods, and the protein can be obtained in this way.
- the protein is produced in glycosylated form in the eukaryotic cells.
- the muteins which are derived from the new proteins by exchange, deletion or addition of amino acids or peptides are preferably prepared by genetic engineering methods.
- the new protein has anticoagulant properties and can be used to prevent and treat vascular diseases such as heart attack, pulmonary embolism, arterial embolism and phlebothrobose. They are also suitable for the preservation of blood.
- vascular diseases such as heart attack, pulmonary embolism, arterial embolism and phlebothrobose. They are also suitable for the preservation of blood.
- One advantage for these uses is the low toxicity of the new protein.
- the new protein is also suitable for the immunization of grazing cattle against tick-specific proteins.
- neutralizing antibodies can disrupt ticks' food intake. This causes the ticks to leave the host and thus die. Examples 1 to 3
- TCA trichloroacetic acid
- This protein mixture (200 mg) was then taken up to a protein concentration of 20 mg / ml in phosphate-buffered saline, pH 5, and applied to a Q-Sepharose® column (Pharmacia Fine Chemicals, fast-f ow).
- the volume of the column was 10 ml.
- the column was equilibrated with the same buffer in which the sample was taken up. After washing the column with three column volumes of squilibration buffer, the column was eluted with a pH gradient.
- 10 column volumes of the wash buffer (pH 5.0) were slowly mixed with 10 column volumes of wash buffer (pH 1 to 3) using a gradient mixer. Under these conditions, the thrombin inhibitor eluted at pH 4.5.
- the protein was thus obtained in a pure and active form. It showed a molecular weight of 15,000 + 1000 in gel electrophoresis.
- the amino-terminal sequence of this protein is: SDYEFPPPKKSRPG. Its isoelectric point is pH 4 to 5.
- the protein which was homogeneous according to molecular weight and obtained according to Example 1 and identified by the thrombin inhibitor effect, was precipitated and dried as described in Example 1 by a 4-fold excess of cold acetone. The residue was then taken up in phosphate-buffered saline, pH 7.5 (protein concentration 20 mg / ml) and placed on a Mono-Q column (column volume 1 ml) equilibrated with the same buffer (approx. 0.1 mg) .
- the column was washed at a flow rate of 0.5 ml / min and then with a gradient of 150 mM NaCl to 350 M NaCl (2.5 ml each) and then of 350 mM NaCl to 450 mM NaCl (2.5 ml each) ), followed by 450 mM NaCl after 550 mM NaCl (10 ml each) and then eluted to 800 mM NaCl.
- the protein appeared between 350 mM NaCl and 550 mM NaCl.
- activity measured as thrombin inhibitor activity
- sequence analysis of all eluted proteins showed that they all have the same amino-terminal sequence and are therefore identical in terms of their primary structure.
- the inactive thrombin inhibitor fraction obtained in 2 was precipitated as described in Example 1 and taken up in a renaturation buffer which contained 8 M urea and 200 mM dithiothreitol (DTT). After 1 h at 37 ° C., the protein was dialyzed against 100 times the volume of phosphate-buffered saline (cut-off volume of the dialysis tube 10 kDa). After 2 h dialysis at 4 ° C., the protein was active and showed the same behavior on the Mono-Q column after elution through a salt gradient as the active fraction in Example 2.
- DTT dithiothreitol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP3931839.7 | 1989-09-23 | ||
DE3931839A DE3931839A1 (de) | 1989-09-23 | 1989-09-23 | Neue proteine und ihre herstellung |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991004275A1 true WO1991004275A1 (fr) | 1991-04-04 |
Family
ID=6390068
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1990/001578 WO1991004275A1 (fr) | 1989-09-23 | 1990-09-18 | Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0493494A1 (fr) |
JP (1) | JPH05500809A (fr) |
CA (1) | CA2054190A1 (fr) |
DE (1) | DE3931839A1 (fr) |
WO (1) | WO1991004275A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008282A1 (fr) * | 1991-10-22 | 1993-04-29 | Basf Aktiengesellschaft | Nouvelle proteine inhibitrice de la thrombine provenant de tiques |
WO1993009231A1 (fr) * | 1991-10-31 | 1993-05-13 | Basf Aktiengesellschaft | Nouvelle proteine inhibitrice de la trombine isolee dans les tiques |
EP0546813A2 (fr) * | 1991-12-10 | 1993-06-16 | Merck & Co. Inc. | Protéines pour l'inhibition de l'adhésion des plaquettes à collagène |
WO1994013807A1 (fr) * | 1992-12-04 | 1994-06-23 | Schering Aktiengesellschaft | Inhibiteur de thrombine provenant de salive de protostomiens |
CN115553287A (zh) * | 2022-10-27 | 2023-01-03 | 北京标驰泽惠生物科技有限公司 | 一种蜱虫保存液及其制备方法和应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4136513A1 (de) * | 1991-11-06 | 1993-05-13 | Basf Ag | Neues thrombininhibitorisches protein aus raubwanzen |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0208507A2 (fr) * | 1985-07-03 | 1987-01-14 | Pitman-Moore Australia Limited | Vaccin contre les tiques |
EP0345614A2 (fr) * | 1988-06-04 | 1989-12-13 | Hoechst Aktiengesellschaft | Amblyommine, un agent modifié pour l'usage en thérapie antithrombotique |
-
1989
- 1989-09-23 DE DE3931839A patent/DE3931839A1/de not_active Withdrawn
-
1990
- 1990-09-18 WO PCT/EP1990/001578 patent/WO1991004275A1/fr not_active Application Discontinuation
- 1990-09-18 CA CA002054190A patent/CA2054190A1/fr not_active Abandoned
- 1990-09-18 EP EP90914720A patent/EP0493494A1/fr not_active Withdrawn
- 1990-09-18 JP JP2513587A patent/JPH05500809A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0208507A2 (fr) * | 1985-07-03 | 1987-01-14 | Pitman-Moore Australia Limited | Vaccin contre les tiques |
EP0345614A2 (fr) * | 1988-06-04 | 1989-12-13 | Hoechst Aktiengesellschaft | Amblyommine, un agent modifié pour l'usage en thérapie antithrombotique |
Non-Patent Citations (5)
Title |
---|
Dialog Information Service, File 351, World Patent Index 81-90, Dialog accession number 3410769, (CSIR) Commonwealth scient org: "Prodn. of vaccine for treating tick paralysis by detoxification of purified tick salivary gland extract", & AU,A,83 16459 (19.01.84) 8410 (Basic). * |
Dialog Information Services, File 155, Medline, Dialog Accession nr. 00345747, Hawkins RI et al.: "Factors affecting blood clotting from the tick ornithodorus moubata", & J. Physiol (London, England), Jul. 1966, 185 (2) p70p. * |
Dialog Information Services, File 155, Medline, Dialog Accession nr. 00754181, Hellman k: "The action of tick extracts on blood coagulation and fibrinolysis", & Thromb Diath Haemorrh, 1967, 18 (3), pages 617-25. * |
Dialog Information Services, File 5, BIOSIS, Dialog Accession nr. 0003310610, Willadsen P et al.: "Biological role of a proeolytic enzyme inhibitor from the ecto parasitic tick boophilus-microplus", & Biochem. J., 189 (2), 1980, 295-304. * |
Science, Band 248, Mai 1990, Lloyed Waxman: "Tick Anticoagulant Peptide (TAP) Is a Novel Inhibitor of Blood Coagulation Factor XA", Seite 593 - 596. * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993008282A1 (fr) * | 1991-10-22 | 1993-04-29 | Basf Aktiengesellschaft | Nouvelle proteine inhibitrice de la thrombine provenant de tiques |
WO1993009231A1 (fr) * | 1991-10-31 | 1993-05-13 | Basf Aktiengesellschaft | Nouvelle proteine inhibitrice de la trombine isolee dans les tiques |
US5585350A (en) * | 1991-10-31 | 1996-12-17 | Basf Aktiengesellschaft | Thrombin-inhibitory protein from ticks |
EP0546813A2 (fr) * | 1991-12-10 | 1993-06-16 | Merck & Co. Inc. | Protéines pour l'inhibition de l'adhésion des plaquettes à collagène |
EP0546813A3 (fr) * | 1991-12-10 | 1994-01-05 | Merck & Co Inc | |
WO1994013807A1 (fr) * | 1992-12-04 | 1994-06-23 | Schering Aktiengesellschaft | Inhibiteur de thrombine provenant de salive de protostomiens |
CN115553287A (zh) * | 2022-10-27 | 2023-01-03 | 北京标驰泽惠生物科技有限公司 | 一种蜱虫保存液及其制备方法和应用 |
CN115553287B (zh) * | 2022-10-27 | 2023-08-08 | 北京标驰泽惠生物科技有限公司 | 一种蜱虫保存液及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2054190A1 (fr) | 1991-03-24 |
DE3931839A1 (de) | 1991-04-04 |
EP0493494A1 (fr) | 1992-07-08 |
JPH05500809A (ja) | 1993-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0471701B2 (fr) | Nouvelles proteines a effet d'inhibition de tnf et leur preparation | |
EP0207956B1 (fr) | Hirudine-pa et ses derives, leur procede de production et leur utilisation | |
DE3689191T2 (de) | Gereinigtes protein mit angiogenischer wirkung und dessen herstellung. | |
DE2429191A1 (de) | Isolierung von koagulationsfaktoren aus biologischem material | |
EP0142860A2 (fr) | Désulfatohirudine, son procédé de préparation et agent pharmaceutique | |
DE68918246T2 (de) | Verbindungen zur Verhinderung von Thrombose. | |
DE19937218A1 (de) | Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie | |
DE3886175T2 (de) | Trigramin, ein Polypeptid, das die Aggregation der Blutplättchen hemmt. | |
EP0101063B1 (fr) | Polypeptide ayant une activité sur le système immunitaire, procédé pour son isolement et sa purification, son application et composition le contenant | |
DE3587526T2 (de) | Serinproteaseinhibitoren und isolierungsverfahren dazu. | |
DE69429062T2 (de) | Thrombin-inhibitoren | |
DE2457047C3 (de) | Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe | |
WO1991004275A1 (fr) | Nouvelles proteines servant a combattre des maladies et a proteger le betail contre les tiques | |
DE3124384C2 (de) | Dermatanpolysulfat, Verfahren zu dessen Herstellung und dieses enthaltendes virushemmendes Mittel | |
DE3914354C1 (fr) | ||
EP0616642B1 (fr) | Nouvelles proteines inhibitrices de thrombine provenant de la sangsue des campagnes | |
DE3850407T2 (de) | Protein mit inhibierender wirkung auf die entzündungserregende phospholipase a2. | |
DE2605576B2 (de) | Verfahren zum Isolieren der Proteasen Papain, Chimopapain, Lysozym und Proteinase X aus dem Milchsaft von Carica papaya und Verwendung der isolierten Proteasen zur Herstellung von sterilisierten und lyophilisierten orthopädischen, neurochirurgischen oder ophthalmologischen Präparaten | |
DE2428955B2 (de) | Verfahren zur Abtrennung der enzymatischen Komponente mit in vivo antikoagulierender und in vitro koagulierender Wirkung aus dem Gift der Schlange Ancistrodon rhodostoma und daraus hergestellte Mittel | |
EP0609242B1 (fr) | Nouvelle proteine inhibitrice de la thrombine provenant de tiques | |
DE4136513A1 (de) | Neues thrombininhibitorisches protein aus raubwanzen | |
AT392003B (de) | Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat | |
WO1993009231A1 (fr) | Nouvelle proteine inhibitrice de la trombine isolee dans les tiques | |
DE69026275T2 (de) | Verfahren zur herstellung von ribonuklease-dimeren | |
DE3213963A1 (de) | Neurotropher faktor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990914720 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2054190 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1990914720 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990914720 Country of ref document: EP |